Karen is a 43-year-old stay-at-home mom.* She was diagnosed with acromegaly two years ago when her primary care physician noticed changes in her facial features. She also had excessive sweating and carpal tunnel syndrome. When her healthcare professional tested Karen's insulin-like growth factor level, it was 600 ng/mL, above the normal age-adjusted range. An endocrinologist confirmed the diagnosis of acromegaly with an oral glucose tolerance test and an MRI of her pituitary gland.
Karen's history
The MRI revealed Karen's pituitary tumor to be small (<10 mm) and surgery to remove it was recommended, but Karen did not want surgery. Her endocrinologist started Karen on Sandostatin LAR® Depot 20 mg IM intragluteally at 4-week intervals to help reduce her growth hormone and growth factor levels.
Karen currently
Although Karen has been taking Sandostatin LAR® Depot for two years, she cannot get used to intramuscular injections. She experiences injection-site pain and a mass under the skin from the large volume of the injection. Her favorite nurse describes Karen as "needle-phobic" and periodically talks to Karen's endocrinologist about alternatives. Karen is looking for an easier way to take medication for acromegaly, and Somatuline® Depot (lanreotide) Injection (lanreotide) Injection offers a short, 20-mm needle and a small, 0.3 to 0.5 mL injection
Do any of your patients resemble Karen?
Last year Somatuline® Depot (lanreotide) Injection helped over 6000 patients with acromegaly,2 including three fictional, but typical, patients named Karen (above), Dave, and Mark (below). See if your patients are like:
* Karen is not an actual patient. Her profile is based on published data from clinical studies and review articles.
